Home » Topics » Drug design, drug delivery and technologies, BioWorld Science

Drug design, drug delivery and technologies, BioWorld Science
RSS

CombiChem reaches second milestone in collaboration with Teijin

Nov. 10, 1999

No Comments

Exelixis and Pharmacia & Upjohn expand collaboration

Nov. 10, 1999

No Comments

ASN presentation for VNA-932, a potent and selective, nonpeptide V2 agonist

Nov. 9, 1999

No Comments

Helix BioPharma finalizes acquisition of PharmaDerm

Nov. 9, 1999

No Comments

Idun identifies X-ray structure of caspase 8

Nov. 8, 1999

No Comments

Abgenix and Pfizer add third antigen target to collaboration agreement

Nov. 5, 1999

No Comments

HepaVec and CSIRO sign option agreement for ovine viral vector technology

Oct. 25, 1999

No Comments

Mechanistically novel iNOS inhibitors identified during Pharmacopeia/Berlex joint project

Oct. 22, 1999

No Comments

Inhale acquires novel particle formulation technology for lung delivery

Oct. 22, 1999

No Comments

Technology acquisition broadens and accelerates ICAgen's R&D programs

Oct. 20, 1999

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Drug design, drug delivery and technologies, BioWorld Science
RSS

CombiChem reaches second milestone in collaboration with Teijin

Exelixis and Pharmacia & Upjohn expand collaboration

ASN presentation for VNA-932, a potent and selective, nonpeptide V2 agonist

Helix BioPharma finalizes acquisition of PharmaDerm

Idun identifies X-ray structure of caspase 8

Abgenix and Pfizer add third antigen target to collaboration agreement

HepaVec and CSIRO sign option agreement for ovine viral vector technology

Mechanistically novel iNOS inhibitors identified during Pharmacopeia/Berlex joint project

Inhale acquires novel particle formulation technology for lung delivery

Technology acquisition broadens and accelerates ICAgen's R&D programs

Today's news in brief

Today's news in brief

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

Proteomics study explores how protein changes influence disease

Abbvie and Simcere enter a $1B T-cell engager deal

Drug design, drug delivery and technologies, BioWorld Science RSS

Drug design, drug delivery and technologies, BioWorld Science
RSS